Compare TEI & NKTR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TEI | NKTR |
|---|---|---|
| Founded | 1993 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 310.3M | 2.2B |
| IPO Year | N/A | 1996 |
| Metric | TEI | NKTR |
|---|---|---|
| Price | $6.44 | $66.24 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $146.67 |
| AVG Volume (30 Days) | 151.2K | ★ 499.1K |
| Earning Date | 01-01-0001 | 05-07-2026 |
| Dividend Yield | ★ 10.51% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $307,711,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 86.00 |
| 52 Week Low | $5.75 | $33.40 |
| 52 Week High | $7.00 | $109.00 |
| Indicator | TEI | NKTR |
|---|---|---|
| Relative Strength Index (RSI) | 35.82 | 38.52 |
| Support Level | $6.24 | $67.11 |
| Resistance Level | $6.68 | $76.49 |
| Average True Range (ATR) | 0.09 | 2.75 |
| MACD | -0.02 | -0.68 |
| Stochastic Oscillator | 0.00 | 4.83 |
Templeton Emerging Markets Income Fund is a closed-end fund. It seeks high, current income, with a secondary goal of capital appreciation, by investing, under normal market conditions. The company's investment portfolio includes Foreign Government and Agency Securities; Quasi-Sovereign and Corporate Bonds; Common Stocks and Other Equity Interests, and Short-Term Investments, and Money Market Funds.
Nektar Therapeutics is a clinical-stage, research-based biopharmaceutical company headquartered in San Francisco, California, and incorporated in Delaware, focused on discovering and developing medicines in the field of immunotherapy. The Company directs its efforts toward creating immunomodulatory agents that selectively induce, amplify, attenuate, or prevent immune responses to achieve desired therapeutic outcomes. Its pipeline of clinical-stage and preclinical-stage immunomodulatory agents targets the treatment of autoimmune diseases, including rezpegaldesleukin, NKTR-0165, NKTR-0166, and NKTR-422, as well as cancer, including NKTR-255.